TY - JOUR T1 - Effect of a single dose of 8 mg moxidectin or 150 µg/kg ivermectin on <em>O. volvulus</em> skin microfilariae in a randomized trial: Differences between areas in the Democratic Republic of the Congo, Liberia and Ghana and impact of intensity of infection JF - medRxiv DO - 10.1101/2022.02.22.22271335 SP - 2022.02.22.22271335 AU - Didier Bakajika AU - Eric M Kanza AU - Nicholas O Opoku AU - Hayford M Howard AU - Germain L Mambandu AU - Amos Nyathirombo AU - Maurice M Nigo AU - Kambale Kasonia Kennedy AU - Safari L Masembe AU - Mupenzi Mumbere AU - Kambale Kataliko AU - Kpehe M Bolay AU - Simon K Attah AU - George Olipoh AU - Sampson Asare AU - Michel Vaillant AU - Christine M Halleux AU - Annette C Kuesel Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/24/2022.02.22.22271335.abstract N2 - Background Community-directed treatment with 150 µg/kg ivermectin (CDTI), the current control strategy, is insufficient for eliminating Onchocerca volvulus transmission across sub-Saharan Africa. Our study in CDTI-naïve areas in Nord Kivu and Ituri (Democratic Republic of the Congo (DRC), Lofa County (Liberia) and Nkwanta district (Ghana) showed that a single 8 mg moxidectin dose reduced skin microfilariae density (microfilariae/mg skin, SmfD) better and for longer than a single 150µg/kg ivermectin dose.Methodology/Principal Findings We analysed drug efficacy by study area and pre-treatment SmfD (intensity of infection, IoI). Four and three IoI categories were defined for across-study and by-study area analyses, respectively. We used a general linear model to analyse SmfD 1, 6, 12 and 18 months post-treatment, a logistic model to determine the odds of undetectable SmfD from month 1 to month 6 (UD1-6), month 12 (UD1-12) and month 18 (UD1-18), and descriptive statistics to quantitate inter-interindividual response differences. Twelve months post-treatment, treatment differences were 92.9%, 90.1%, 86.8% and 84.5% in Nord Kivu, Ituri, Lofa and Nkwanta, and 74.1%, 84.2%, 90.0% and 95.4% for participants with SmfD 10-20, ≥20-&lt;50, ≥50-&lt;80, ≥80, respectively. Ivermectin’s efficacy was lower in Ituri and Nkwanta than Nord Kivu and Lofa (p≤0.002) and moxidectin’s efficacy lower in Nkwanta than Nord Kivu, Ituri and Lofa (p&lt;0.006). Odds ratios for UD1-6, UD1-12 or UD1-18 after moxidectin versus ivermectin treatment exceeded 7.0. Suboptimal response (SmfD 12 months post-treatment &gt;40% of pre-treatment SmfD) occurred in 0%, 0.3%, 1.6% and 3.9% of moxidectin and 12.1%, 23.7%, 10.8% and 28.0% of ivermectin treated participants in Nord Kivu, Ituri, Lofa and Nkwanta, respectively.Conclusions/significance The benefit of moxidectin vs ivermectin treatment increased with pre-treatment IoI. The possibility that parasite populations in different areas have different drug susceptibility without prior ivermectin selection pressure needs to be considered and further investigated.Author Summary Onchocerciasis or river blindness is a parasitic disease primarily in sub-Saharan Africa and Yemen. It can cause debilitating morbidity including severe itching, skin changes, visual impairment and even blindness. Many years of control efforts, today primarily based on mass administration of ivermectin (MDA) in endemic communities, have reduced morbidity and the percentage of infected individuals so that elimination of parasite transmission is now planned. WHO estimated that in 2020 more than 239 million people required MDA. Ivermectin may not be sufficiently efficacious to achieve elimination everywhere. Our study in areas in Liberia, Ghana and the Democratic Republic of the Congo where MDA had not been implemented yet showed that moxidectin reduced parasite levels in the skin better and for longer than ivermectin. Here we show that people with higher numbers of parasites in the skin benefit more from moxidectin treatment than those with lower numbers and that the efficacy of ivermectin and moxidectin differs between study areas. Provided WHO and countries include moxidectin in guidelines and policies, this information could help decisions on when and where to use moxidectin.Competing Interest StatementI have read the journal's policy and the authors of this manuscript have the following competing interests: ACK and CMH are staff of WHO which funded the work of all co-authors on the study whose data are analysed here through its department UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR).Clinical TrialNCT00790998Funding StatementWHO/TDR funded this study, utilizing contributions from the WHO African Programme for Onchocerciasis Control (APOC), 6.3 million $US from Wyeth and following its acquisition by Pfizer, Pfizer, and WHO/TDR donor countries. Wyeth provided drug for this study and contributed to the study protocol. Wyeth prepared the submissions to the Ministries of Health and provided data management services until July 3, 2011. Pfizer was not further involved in this study in any way, including data verification or analysis and has not commented on this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Conduct of this study, including protocol, information documents for potential participants and the participant consent forms, were approved by the Ghana Food and Drugs Authority and the Ghana Health Service Ethics Review Committee, the Liberia Ministry of Health and Social Welfare and the Ethics Committee of the Liberia Institute for Biomedical Research, the Ministere de la Sante Publique of DRC and the Ethics Committee of the Ecole de la Sante Publique Universite de Kinshasa in DRC, and the WHO Ethics Review Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesParticipants consented to publication of summaries of the results, not to sharing of their individual data. Consequently, the Sponsor (WHO) and the authors do not have the participants permission to make individual participant data publicly available. Individuals wanting to analyze the data should contact the Sponsor (via the corresponding author or tdr at who.int) or Medicines Development for Global Health to which WHO has licensed the data (via mark.sullivan at medicinesdevelopment.com). Requests should include the objectives, data analysis plan and plans to obtain applicable Ethics Committee approvals and involve the investigators (co-authors on this manuscript) and commitment to not share the data with anybody else. ER -